Befuraline

From Wikipedia, the free encyclopedia

This is an old revision of this page, as edited by The Nth User (talk | contribs) at 22:28, 19 August 2019 (→‎References: Replaced two categories with one subcategory). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

Befuraline
Clinical data
ATC code
  • none
Identifiers
  • 1-benzofuran-2-yl(4-benzylpiperazin-1-yl)methanone
CAS Number
PubChem CID
ChemSpider
UNII
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC20H20N2O2
Molar mass320.385 g/mol g·mol−1
3D model (JSmol)
  • O=C(N1CCN(CC1)CC2=CC=CC=C2)C3=CC4=C(C=CC=C4)O3
  • InChI=1S/C20H20N2O2/c23-20(19-14-17-8-4-5-9-18(17)24-19)22-12-10-21(11-13-22)15-16-6-2-1-3-7-16/h1-9,14H,10-13,15H2 checkY
  • Key:SRIJFPBZWUFLFD-UHFFFAOYSA-N checkY
  (verify)

Befuraline (DIV-154) is a psychoactive drug and member of the piperazine chemical class which was developed in Germany in the 1970s.[1] Befuraline has stimulant and antidepressant effects and has seen some use in Germany and France, although it has never become widely used.[2] Befuraline's active metabolite benzylpiperazine is responsible for its effects.[citation needed]

See also

References

  1. ^ Boksay IJ, Popendiker K, Weber RO, Soder A. Synthesis and pharmacological activity of befuraline (N-benzo[b]furan-2-ylcarbonyl-N'-benzylpiperazine), a new antidepressant compound. Arzneimittel-Forschung. 1979;29(2):193-204.
  2. ^ Gastpar M, Gastpar G, Gilsdorf U. Befuraline, its safety and efficacy in depressed inpatients. Pharmacopsychiatry. 1985 Nov;18(6):351-5.